Faster, Cost-Effective Preclinical Drug Validation with Functional Diagnosis

LIDE specializes in preclinical studies, offering traditional R&D in-vitro and in-vivo services but recommend a better R&D roadmap for potential drug candidates - we call this platform Functional Diagnosis:

Functional Diagnosis Study Roadmap:

  1. Use conditionally reprogrammed (CR) cells instead of genetically engineered cell lines for in-vitro studies, providing a more representative starting point that has maintained cell heterogeneity.
  2. Testing or validating indications by leveraging our MiniPDX before PDX studies, a faster, more cost-effective feedback mechanism before more costly investments. 
  3. Running traditional, gold-standard PDX studies to support IND candidates.
  4. Applying OMICS analysis and MiniPDX® with fresh patient samples to identify biomarkers to inform patient stratification and recruitment strategy

Benefits of Functional Diagnosis:

  • Better quality testing with CR cells and PDX models derived from fresh patient samples
  • Earlier, cheaper and faster in-vivo validation with MiniPDX® 7-day drug screen
  • Increased likelihood of success in clinical trials with OMICS analysis

Functional Diagnosis leverages LIDE's Translational Medicine platform. We are participating in a real-world study that offers cancer patients personalized treatment recommendations. This has helped LIDE receive models of rare cancer types, hard-to-find genetic mutations and drug resistant tissues, with 1700+ PDX models and many high profile expression phenotypes.

Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform

Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform